



Study	I ²		Odds Ratio (95% CrI)
-------	----------------	--	----------------------


Placebo vs Erlotinib




Rociletinib vs Erlotinib




antiangio vs Erlotinib




Gefitinib vs Furmonertinib




Osimertinib vs Gefitinib_Erlotinib



0.03 1 30





Study	I ²
Placebo vs Osimertinib	
10	
r19	
Pooled (pair-wise)	71.4%
Indirect (back-calculated)	
Pooled (network)	10.6%

